^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMM40H
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ImmuneOnco Biopharma
Drug class:
CD70 inhibitor
Related drugs:
Phase 1
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Not yet recruiting
Last update posted :
09/22/2022
Initiation :
09/01/2022
Primary completion :
10/01/2023
Completion :
06/01/2024
PD-L1
|
IMM40H
Share
